The progress of targeted therapies has a new perspective in SEGA’s treatment; it is the inhibitor of mTOR (everolimus) that indicates from the age of 12 months in subependymal giant cell astrocytoma associated with tuberous sclerosis complex requiring therapeutic intervention but not eligible for surgical resection. This evidence concerns the gene MTOR and astrocytoma (excluding glioblastoma).